Microvessel density of malignant and benign hepatic lesions and MRI evaluation

被引:10
作者
Lu, Jian-Ping [1 ]
Wang, Jian [1 ]
Wang, Tao [2 ]
Wang, Yi [2 ]
Wu, Wei-Qing [2 ]
Gao, Li [3 ]
机构
[1] Second Mil Med Univ, Changhai Hosp, Dept Radiol, Shanghai 200433, Peoples R China
[2] Second Mil Med Univ, Eastern Hepatobiliary Surg Inst, Shanghai 200433, Peoples R China
[3] Second Mil Med Univ, Changhai Hosp, Dept Pathol, Shanghai 200433, Peoples R China
基金
中国国家自然科学基金;
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To study the difference of microvessel density (MVD) between malignant and benign hepatic lesions and study the relationship between MVD and dynamic enhanced magnetic resonance imaging (MRI) for evaluation of microvessels within malignant and benign hepatic lesions. METHODS: A total of 265 specimens of hepatocellular carcinoma (HCC), 122 cirrhosis tissues and 22 hepatic benign lesions were enrolled for MVD by immunohistochemistry on tissue microarray, of which 49 underwent MRI examination before surgery, then contrast-to-noise ratios (CNR) and enhancement index (EI) in all the phases were calculated. Pearson correlation was performed for correlation analysis between CNR, EI and MVD. RESULTS: MVD of HCC was 22.7 +/- 15.8 (mean +/- SD), which was obviously higher than that of cirrhosis tissue (8.3 +/- 7.6, P<0.01), but was not statistically different from that of benign lesions (31.3 +/- 22.7, P>0.05). Among HCC, MVD of gradesIII was 29.9 +/- 18.6, which was much higher than those of grade III (22.2 +/- 18.2, P<0.01) and gradeIV (22.9 +/- 19.0, P<0.01). MVD of HCC (P=0.018) and of benign lesions (P=0.014) were both correlative with CNR in arterial phase. CONCLUSION: Neoangiogenesis is an important feature for malignant tumor, and MVD may act as a biological marker in differentiating malignant from benign hepatic lesions. Dynamic enhanced MRI, especially image in arterial phase, may act as an MVD evaluation criterion for malignant and benign hepatic lesions.
引用
收藏
页码:1730 / 1734
页数:5
相关论文
共 34 条
[1]
Bubendorf L, 1999, CANCER RES, V59, P803
[2]
de Boer WB, 2000, CANCER CYTOPATHOL, V90, P273, DOI 10.1002/1097-0142(20001025)90:5<273::AID-CNCR2>3.0.CO
[3]
2-M
[4]
Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver [J].
El-Assal, ON ;
Yamanoi, A ;
Soda, Y ;
Yamaguchi, M ;
Igarashi, M ;
Yamamoto, A ;
Nabika, T ;
Nagasue, N .
HEPATOLOGY, 1998, 27 (06) :1554-1562
[5]
Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study [J].
Frachon, S ;
Gouysse, G ;
Dumortier, J ;
Couvelard, A ;
Nejjari, M ;
Mion, F ;
Berger, F ;
Paliard, P ;
Boillot, O ;
Scoazec, JY .
JOURNAL OF HEPATOLOGY, 2001, 34 (06) :850-857
[6]
Implications of human macrophage metalloelastase and vascular endothelial growth factor gene expression in angiogenesis of hepatocellular carcinoma [J].
Gorrin-Rivas, MJ ;
Arii, S ;
Mori, A ;
Takeda, Y ;
Mizumoto, M ;
Furutani, M ;
Imamura, M .
ANNALS OF SURGERY, 2000, 231 (01) :67-73
[7]
Use of CD34 and factor VIII to diagnose hepatocellular carcinoma on fine needle aspirates [J].
Gottschalk-Sabag, S ;
Ron, N ;
Glick, T .
ACTA CYTOLOGICA, 1998, 42 (03) :691-696
[8]
Tissue microarray technology for high-throughput molecular profiling of cancer [J].
Kallioniemi, OP ;
Wagner, U ;
Kononen, J ;
Sauter, G .
HUMAN MOLECULAR GENETICS, 2001, 10 (07) :657-662
[9]
Ker CG, 1999, HEPATO-GASTROENTEROL, V46, P646
[10]
Kimura H, 1998, LIVER, V18, P14